Edap Tms S.A. (NASDAQ:EDAP)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Monday. They currently have a $6.50 target price on the medical equipment provider’s stock. HC Wainwright’s price objective suggests a potential upside of 101.86% from the stock’s previous close.

Several other equities research analysts also recently issued reports on EDAP. Zacks Investment Research downgraded shares of Edap Tms from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 24th. ValuEngine downgraded shares of Edap Tms from a “hold” rating to a “sell” rating in a research note on Friday, September 1st.

Edap Tms (EDAP) traded down 0.93% during trading on Monday, hitting $3.19. The stock had a trading volume of 141,023 shares. Edap Tms has a 12-month low of $2.25 and a 12-month high of $3.85. The stock has a 50 day moving average price of $2.94 and a 200 day moving average price of $2.91. The company’s market capitalization is $92.50 million.

Edap Tms (NASDAQ:EDAP) last issued its earnings results on Wednesday, August 23rd. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.03). Edap Tms had a negative net margin of 0.27% and a positive return on equity of 10.31%. The firm had revenue of $10.40 million during the quarter, compared to analyst estimates of $10.00 million. During the same quarter last year, the business posted $0.10 earnings per share. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. Equities research analysts forecast that Edap Tms will post $0.01 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/09/hc-wainwright-reiterates-buy-rating-for-edap-tms-s-a-edap.html.

A number of hedge funds have recently modified their holdings of the business. Archon Capital Management LLC acquired a new stake in Edap Tms during the second quarter worth approximately $2,474,000. Virtu KCG Holdings LLC acquired a new stake in Edap Tms during the second quarter worth approximately $117,000. Hilton Capital Management LLC lifted its position in Edap Tms by 43.1% during the second quarter. Hilton Capital Management LLC now owns 83,000 shares of the medical equipment provider’s stock worth $274,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Essex Investment Management Co. LLC acquired a new stake in Edap Tms during the second quarter worth approximately $172,000. Hedge funds and other institutional investors own 9.41% of the company’s stock.

Edap Tms Company Profile

EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.

Receive News & Ratings for Edap Tms S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms S.A. and related companies with MarketBeat.com's FREE daily email newsletter.